New hope for scarred lungs: experimental drug enters patient testing
NCT ID NCT06747923
Summary
This study is testing a new oral drug called SB17170 for people with idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. About 30 patients will take either the drug or a placebo pill daily for 12 weeks to see if it helps slow the decline in lung function and improves quality of life. The main goal is to measure changes in how much air a person can forcefully exhale, a key test for lung health.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ajou University Hospital
NOT_YET_RECRUITINGSuwon, South Korea
Contact
-
Chung-Ang University Gwangmyeong Hospital
RECRUITINGGwangmyeong, South Korea
Contact
-
Myong Ji Hospital
RECRUITINGGoyang, South Korea
Contact
-
Seoul Asan Hospital
NOT_YET_RECRUITINGSeoul, South Korea
Contact
-
The Catholic Univ. of Korea Seoul St. Mary's Hospital
NOT_YET_RECRUITINGSeoul, South Korea
Contact
Conditions
Explore the condition pages connected to this study.